Table of Contents

Research Articles: Therapeutics, Targets, and Development

• Research Articles: Therapeutics, Targets, and Development

  Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data

  Lawrence P. Petalidis, Anastasis Oulas, Magnus Backlund, Matthew T. Wayland, Lu Liu, Karen Plant, Lisa Happerfield, Tom C. Freeman, Panayiota Poirazi and V. Peter Collins

  Mol Cancer Ther May 1 2008 7 (5) 1013-1024; DOI:10.1158/1535-7163.MCT-07-0177

  
  
• Research Articles: Therapeutics, Targets, and Development

  An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector

  Guozheng Liu, Shuping Dou, Mary Rusckowski and Donald J. Hnatowich

  Mol Cancer Ther May 1 2008 7 (5) 1025-1032; DOI:10.1158/1535-7163.MCT-07-2203

  
  
• Research Articles: Therapeutics, Targets, and Development

  Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia

  Athanasia Katsoulas, Zakaria Rachid, James P. McNamee, Christopher Williams and Bertrand J. Jean-Claude

  Mol Cancer Ther May 1 2008 7 (5) 1033-1043; DOI:10.1158/1535-7163.MCT-07-0179

  
  
• Research Articles: Therapeutics, Targets, and Development

  Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein

  Hui Wang, Kai Chen, Weibo Cai, Zibo Li, Lina He, Amir Kashefi and Xiaoyuan Chen

  Mol Cancer Ther May 1 2008 7 (5) 1044-1053; DOI:10.1158/1535-7163.MCT-07-2084

  
  
• Research Articles: Therapeutics, Targets, and Development

  KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo

  Christian A. Hassig, Kent T. Symons, Xin Guo, Phan-Manh Nguyen, Tami Annable, Paul L. Wash, Joseph E. Payne, David A. Jenkins, Céline Bonnefous, Carol Trotter, Yan Wang, John V. Anzola, Elena L. Milkova, Timothy Z. Hoffman, Sara J. Dozier, Brandon M. Wiley, Alan Saven, James W. Malecha, Robert L. Davis, Jerry Muhammad, Andrew K. Shiau, Stewart A. Noble, Tadimeti S. Rao, Nicholas D. Smith and Jeffrey H. Hager

  Mol Cancer Ther May 1 2008 7 (5) 1054-1065; DOI:10.1158/1535-7163.MCT-07-2347

  
  
• Research Articles: Therapeutics, Targets, and Development

  Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

  Andrea Newbold, Ralph K. Lindemann, Leonie A. Cluse, Kate F. Whitecross, Anthony E. Dear and Ricky W. Johnstone

  Mol Cancer Ther May 1 2008 7 (5) 1066-1079; DOI:10.1158/1535-7163.MCT-07-2256

  
  
• Research Articles: Therapeutics, Targets, and Development

  Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor

  Adriana S. Beltran, Xueguang Sun, Paul M. Lizardi and Pilar Blancafort

  Mol Cancer Ther May 1 2008 7 (5) 1080-1090; DOI:10.1158/1535-7163.MCT-07-0526

  
  
• Research Articles: Therapeutics, Targets, and Development

  Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3′-untranslated region

  Karthikeyan Kandasamy and Andrew S. Kraft

  Mol Cancer Ther May 1 2008 7 (5) 1091-1100; DOI:10.1158/1535-7163.MCT-07-2368

  
  
• Research Articles: Therapeutics, Targets, and Development

  Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells

  Ningxi Zhu, Lubing Gu, Fengzhi Li and Muxiang Zhou

  Mol Cancer Ther May 1 2008 7 (5) 1101-1109; DOI:10.1158/1535-7163.MCT-08-0179

  
  
• Research Articles: Therapeutics, Targets, and Development

  Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia

  Shuiying Hu, Hongmei Niu, Patton Minkin, Shelley Orwick, Akira Shimada, Hiroto Inaba, Gary V.H. Dahl, Jeffrey Rubnitz and Sharyn D. Baker

  Mol Cancer Ther May 1 2008 7 (5) 1110-1120; DOI:10.1158/1535-7163.MCT-07-2218

  
  
• Research Articles: Therapeutics, Targets, and Development

  Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

  Ellen Weisberg, Renee D. Wright, Douglas W. McMillin, Constantine Mitsiades, Arghya Ray, Rosemary Barrett, Sophia Adamia, Richard Stone, Ilene Galinsky, Andrew L. Kung and James D. Griffin

  Mol Cancer Ther May 1 2008 7 (5) 1121-1129; DOI:10.1158/1535-7163.MCT-07-2331

  
  
• Research Articles: Therapeutics, Targets, and Development

  Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells

  Ismael Samudio, Svitlana Kurinna, Peter Ruvolo, Borys Korchin, Hagop Kantarjian, Miloslav Beran, Kenneth Dunner Jr., Seiji Kondo, Michael Andreeff and Marina Konopleva

  Mol Cancer Ther May 1 2008 7 (5) 1130-1139; DOI:10.1158/1535-7163.MCT-07-0553

  
  
• Research Articles: Therapeutics, Targets, and Development

  Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells

  Anna Morena D'Alise, Giovanni Amabile, Mariangela Iovino, Francesco Paolo Di Giorgio, Marta Bartiromo, Fabio Sessa, Fabrizio Villa, Andrea Musacchio and Riccardo Cortese

  Mol Cancer Ther May 1 2008 7 (5) 1140-1149; DOI:10.1158/1535-7163.MCT-07-2051

  
  
• Research Articles: Therapeutics, Targets, and Development

  MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer

  Tetsuya Oguri, Hiroaki Ozasa, Takehiro Uemura, Yuji Bessho, Mikinori Miyazaki, Ken Maeno, Hiroyoshi Maeda, Shigeki Sato and Ryuzo Ueda

  Mol Cancer Ther May 1 2008 7 (5) 1150-1155; DOI:10.1158/1535-7163.MCT-07-2088

  
  
• Research Articles: Therapeutics, Targets, and Development

  Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells

  Xia Wang, Wenshu Chen, Weihua Zeng, Lang Bai, Yohannes Tesfaigzi, Steven A. Belinsky and Yong Lin

  Mol Cancer Ther May 1 2008 7 (5) 1156-1163; DOI:10.1158/1535-7163.MCT-07-2183

  
  
• Research Articles: Therapeutics, Targets, and Development

  p27^Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis

  Monica Schiappacassi, Francesca Lovat, Vincenzo Canzonieri, Barbara Belletti, Stefania Berton, Domenica Di Stefano, Andrea Vecchione, Alfonso Colombatti and Gustavo Baldassarre

  Mol Cancer Ther May 1 2008 7 (5) 1164-1175; DOI:10.1158/1535-7163.MCT-07-2154

  
  
• Research Articles: Therapeutics, Targets, and Development

  LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells

  Daniel B. Lipka, Linda S. Hoffmann, Florian Heidel, Boyka Markova, Marie-Christine Blum, Frank Breitenbuecher, Stefan Kasper, Thomas Kindler, Ross L. Levine, Christoph Huber and Thomas Fischer

  Mol Cancer Ther May 1 2008 7 (5) 1176-1184; DOI:10.1158/1535-7163.MCT-07-2215

  
  
• Research Articles: Therapeutics, Targets, and Development

  SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells

  Adina Vultur, Ralf Buettner, Claudia Kowolik, Wei Liang, David Smith, Frank Boschelli and Richard Jove

  Mol Cancer Ther May 1 2008 7 (5) 1185-1194; DOI:10.1158/1535-7163.MCT-08-0126

  
  
• Research Articles: Therapeutics, Targets, and Development

  Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9

  Cheng-Wei Lin, Shing-Chun Shen, Wen-Chi Hou, Liang-Yo Yang and Yen-Chou Chen

  Mol Cancer Ther May 1 2008 7 (5) 1195-1206; DOI:10.1158/1535-7163.MCT-07-2199

  
  
• Research Articles: Therapeutics, Targets, and Development

  Requirement of hypoxia-inducible factor-1α down-regulation in mediating the antitumor activity of the anti–epidermal growth factor receptor monoclonal antibody cetuximab

  Xinqun Li, Yang Lu, Ke Liang, Tianhong Pan, John Mendelsohn and Zhen Fan

  Mol Cancer Ther May 1 2008 7 (5) 1207-1217; DOI:10.1158/1535-7163.MCT-07-2187

  
  
• Research Articles: Therapeutics, Targets, and Development

  Cytotoxicity of the matrix metalloproteinase–activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells

  Randall W. Alfano, Stephen H. Leppla, Shihui Liu, Thomas H. Bugge, Meenhard Herlyn, Keiran S. Smalley, Jennifer L. Bromberg-White, Nicholas S. Duesbery and Arthur E. Frankel

  Mol Cancer Ther May 1 2008 7 (5) 1218-1226; DOI:10.1158/1535-7163.MCT-08-0024

  
  
• Research Articles: Therapeutics, Targets, and Development

  Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis

  Shang-Chiung Chen, Dale O. Henry, Peter R. Reczek and Michael K.K. Wong

  Mol Cancer Ther May 1 2008 7 (5) 1227-1236; DOI:10.1158/1535-7163.MCT-08-0051

  
  
• Research Articles: Therapeutics, Targets, and Development

  Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors

  Gunnar Johansson, Yonatan Y. Mahller, Margaret H. Collins, Mi-Ok Kim, Takahiro Nobukuni, John Perentesis, Timothy P. Cripe, Heidi A. Lane, Sara C. Kozma, George Thomas and Nancy Ratner

  Mol Cancer Ther May 1 2008 7 (5) 1237-1245; DOI:10.1158/1535-7163.MCT-07-2335

  
  
• Research Articles: Therapeutics, Targets, and Development

  Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1

  Rui Gao, Douglas K. Price, Tristan Sissung, Eddie Reed and William D. Figg

  Mol Cancer Ther May 1 2008 7 (5) 1246-1250; DOI:10.1158/1535-7163.MCT-07-2206

  
  
• Research Articles: Therapeutics, Targets, and Development

  The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis

  Karen Liby, Candice C. Black, Darlene B. Royce, Charlotte R. Williams, Renee Risingsong, Mark M. Yore, Xi Liu, Tadashi Honda, Gordon W. Gribble, William W. Lamph, Thomas A. Sporn, Ethan Dmitrovsky and Michael B. Sporn

  Mol Cancer Ther May 1 2008 7 (5) 1251-1257; DOI:10.1158/1535-7163.MCT-08-0023

  
  
• Research Articles: Therapeutics, Targets, and Development

  Chemopreventive effects of oral gallic acid feeding on tumor growth and progression in TRAMP mice

  Komal Raina, Subapriya Rajamanickam, Gagan Deep, Meenakshi Singh, Rajesh Agarwal and Chapla Agarwal

  Mol Cancer Ther May 1 2008 7 (5) 1258-1267; DOI:10.1158/1535-7163.MCT-07-2220

  
  
• Research Articles: Therapeutics, Targets, and Development

  Vitamin D₃ analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57

  Lianjun Lu, Jianhua Qiu, Shunli Liu and Wenjing Luo

  Mol Cancer Ther May 1 2008 7 (5) 1268-1274; DOI:10.1158/1535-7163.MCT-07-2222

  
  
• Research Articles: Therapeutics, Targets, and Development

  Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis

  Po-Lin So, Michele A. Fujimoto and Ervin H. Epstein Jr.

  Mol Cancer Ther May 1 2008 7 (5) 1275-1284; DOI:10.1158/1535-7163.MCT-07-2043

  
  
• Research Articles: Therapeutics, Targets, and Development

  Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity

  Tatjana Mijatovic, Nancy De Nève, Philippe Gailly, Véronique Mathieu, Benjamin Haibe-Kains, Gianluca Bontempi, Javier Lapeira, Christine Decaestecker, Vincenzo Facchini and Robert Kiss

  Mol Cancer Ther May 1 2008 7 (5) 1285-1296; DOI:10.1158/1535-7163.MCT-07-2241

  
  
• Research Articles: Therapeutics, Targets, and Development

  PBISe, a novel selenium-containing drug for the treatment of malignant melanoma

  SubbaRao V. Madhunapantula, Dhimant Desai, Arati Sharma, Sung Jin Huh, Shantu Amin and Gavin P. Robertson

  Mol Cancer Ther May 1 2008 7 (5) 1297-1308; DOI:10.1158/1535-7163.MCT-07-2267

  
  
• Research Articles: Therapeutics, Targets, and Development

  Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin

  José A. Casado, Paula Río, Esther Marco, Verónica García-Hernández, Alberto Domingo, Laura Pérez, Juan Carlos Tercero, Juan José Vaquero, Beatriz Albella, Federico Gago and Juan A. Bueren

  Mol Cancer Ther May 1 2008 7 (5) 1309-1318; DOI:10.1158/1535-7163.MCT-07-2432

  
  
• Research Articles: Therapeutics, Targets, and Development

  Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78

  Minal Kotecha, Jerome Kluza, Geoff Wells, C. Caroline O'Hare, Claudia Forni, Roberto Mantovani, Philip W. Howard, Peter Morris, David E. Thurston, John A. Hartley and Daniel Hochhauser

  Mol Cancer Ther May 1 2008 7 (5) 1319-1328; DOI:10.1158/1535-7163.MCT-07-0475

  
  
• Research Articles: Therapeutics, Targets, and Development

  Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice

  Tao Bian, Yue Wang, Zhenhua Lu, Zhenmei Ye, Li Zhao, Jiao Ren, Hui Zhang, Li Ruan and Houwen Tian

  Mol Cancer Ther May 1 2008 7 (5) 1329-1335; DOI:10.1158/1535-7163.MCT-07-2015